Cardiac safety profiles of first-generation vs second-generation BTK inhibitors: a meta-analysis
The Oncologist · 10.04.2026 · 31 (5)
DOI: 10.1093/oncolo/oyag102 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift The Oncologist, online erschienen am 23.03.2026. Verfasst von Ali Mushtaq und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Cleveland Clinic, Cleveland, OH, 44195, United States. Hauptthemen laut MEDLINE: Agammaglobulinaemia Tyrosine Kinase, Atrial Fibrillation, Cardiotoxicity, Protein Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The first-generation Bruton’s tyrosine kinase inhibitor (BTKi), ibrutinib, is associated with significant cardiotoxicity. Second-generation agents were developed to mitigate this risk and offer an improved safety profile. This systematic review and meta-analysis of six direct comparator studies compares the cardiac safety profiles of first- and second-generation BTKi.
Methods
We systematically searched Medline, Embase, and Cochrane for studies directly comparing first- and second-generation BTKi. Data from 6 studies, encompassing 14 455 patients (12 816 in the first-generation arm and 1639 in the second-generation arm), were included. The primary outcomes were the incidence of atrial fibrillation (AF) and cardiac events, defined by the Medical Dictionary for Regulatory Activities system organ class. All pooled analyses were conducted using a random-effects model. Publication bias was evaluated visually using a funnel plot, quantitatively with Egger’s regression test, and corrected using the Duval and Tweedie trim-and-fill method.
Results
Compared to second-generation agents, ibrutinib was associated with a significantly higher risk of AF (OR 2.50, 95% CI, 1.97-3.17), total cardiac events (OR 1.53, 95% CI, 1.18-1.99), and heart failure (OR 2.08, 95% CI, 1.13-3.83). This translated to a 3-fold higher rate of treatment discontinuation for a cardiac cause (OR 3.32, 95% CI, 1.46-7.55). No significant difference in all-cause mortality was found.
Conclusion
Second-generation BTKi may provide a more favorable cardiovascular safety profile than ibrutinib, resulting in fewer key cardiac events and less treatment-limiting toxicity. These findings should inform clinical decision-making, especially for patients with increased risk for cardiovascular disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Cleveland Clinic, Cleveland, OH, 44195, United States.
- College of Medicine, Alfaisal University, Riyadh, 11533, Saudi Arabia.
- Department of Cardiology, Cleveland Clinic, Cleveland, OH, 44195, United States.
- Indiana University School of Medicine Department of Internal Medicine, Indianapolis, IN, 46202, United States.
- Department of Medicine, Creighton University School of Medicine, Omaha, NE, 68178, United States.
- Department of Internal Medicine Henry Ford St. John Hospital, Detroit, MI, 48236, United States.
ORCID-Profile: Eman Nayaz Ahmed, Rohit Moudgil, Moaath K Mustafa Ali
Zitieren
APA
Mushtaq, A., Ahmed, E. N., Aljumaa, R., E'mar, A. R., Badwan, O., Ashruf, O., Elshaer, A., Shaik, A., Baroudi, M., Moudgil, R., & Mustafa Ali, M. K. (2026). Cardiac safety profiles of first-generation vs second-generation BTK inhibitors: a meta-analysis. The Oncologist, 31(5). https://doi.org/10.1093/oncolo/oyag102
Vancouver
Mushtaq A, Ahmed EN, Aljumaa R, E'mar AR, Badwan O, Ashruf O, et al. Cardiac safety profiles of first-generation vs second-generation BTK inhibitors: a meta-analysis. The Oncologist. 2026;31(5). doi:10.1093/oncolo/oyag102
BibTeX
@article{Mushtaq2026,
author = {Mushtaq, Ali and Ahmed, Eman Nayaz and Aljumaa, Roaa and E'mar, Abdel Rahman and Badwan, Osamah and Ashruf, Omer and Elshaer, Ahmad and Shaik, Abdullah and Baroudi, Mohanad and Moudgil, Rohit and Mustafa Ali, Moaath K},
title = {Cardiac safety profiles of first-generation vs second-generation BTK inhibitors: a meta-analysis},
journal = {The Oncologist},
year = {2026},
volume = {31},
number = {5},
doi = {10.1093/oncolo/oyag102}
}
EUVIMED